Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trialJosep M. Llovet, Peiguo Cao, Ruocai Xu et al.|The Lancet Oncology|2023Cited by 436
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III TrialShukui Qin, Feng Chen, Feng Bi et al.|Journal of Clinical Oncology|2021Cited by 417
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.Feng Bi, Feng Chen, Shukui Qin et al.|Journal of Clinical Oncology|2020Cited by 39